Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion

被引:60
作者
Rosenbauer, F
Kallies, A
Scheller, M
Knobeloch, KP
Rock, CO
Schwieger, M
Stocking, C
Horak, I
机构
[1] Free Univ Berlin, Inst Mol Pharmacol, Dept Mol Genet, D-12207 Berlin, Germany
[2] Free Univ Berlin, Benjamin Franklin Med Ctr, D-12207 Berlin, Germany
[3] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA
[4] Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany
关键词
adhesion; Dab2; ICSBP; IFN-7; myelopoiesis;
D O I
10.1093/emboj/21.3.211
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mice lacking transcription factor interferon consensus sequence binding protein (ICSBP) develop a syndrome similar to human chronic myeloid leukemia and are immunodeficient. In order to define the molecular mechanisms responsible for the cellular defects of ICSBP-/- mice, we used bone marrow-derived macrophages (BMM) to identify genes deregulated in the absence of ICSBP. Here, we report that disabled-2 (Dab2), a signal phosphoprotein, is transcriptionally up-regulated and accumulates in the cytoskeleton/membrane fraction of ICSBP-/- BMM. Moreover, our results revealed Dab2 as a novel IFN-gamma-response gene. Both ICSBP and the Ets-transcription factor PU.1 bind to the Dab2 promoter, whereby ICSBP represses PU.1-induced Dab2 promoter transactivation in vitro. Notably, repression of Dab2 expression by ICSBP is also found in myeloid progenitors. Overexpression of Dab2 leads to accelerated cell adhesion and spreading, accompanied by enhanced actin fiber formation. Furthermore, cell adhesion induces transient Dab2 phosphorylation and its translocation to the cytoskeletal/membrane fraction. Our results identify a novel role of Dab2 as an inducer of cell adhesion and spreading, and strongly suggest that the up-regulation of Dab2 contributes to the hematopoietic defect seen in ICSBP-/- mice.
引用
收藏
页码:211 / 220
页数:10
相关论文
共 39 条
[1]   Sequence, genomic structure, and chromosomal assignment of human DOC-2 [J].
Albertsen, HM ;
Smith, SA ;
Melis, R ;
Williams, B ;
Holik, P ;
Stevens, J ;
White, R .
GENOMICS, 1996, 33 (02) :207-213
[2]   NOVEL RETROVIRAL VECTORS FOR EFFICIENT EXPRESSION OF THE MULTIDRUG-RESISTANCE (MDR-1) GENE IN EARLY HEMATOPOIETIC-CELLS [J].
BAUM, C ;
HEGEWISCHBECKER, S ;
ECKERT, HG ;
STOCKING, C ;
OSTERTAG, W .
JOURNAL OF VIROLOGY, 1995, 69 (12) :7541-7547
[3]   c-Jun is a JNK-independent coactivator of the PU.1 transcription factor [J].
Behre, G ;
Whitmarsh, AJ ;
Coghlan, MP ;
Hoang, T ;
Carpenter, CL ;
Zhang, DE ;
Davis, RJ ;
Tenen, DG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (08) :4939-4946
[4]   Pip, a lymphoid-restricted IRF, contains regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1 [J].
Brass, AL ;
Kehrli, E ;
Eisenbeis, CF ;
Storb, U ;
Singh, H .
GENES & DEVELOPMENT, 1996, 10 (18) :2335-2347
[5]   Suppression of IL-12 transcription in macrophages following Fcγ receptor ligation [J].
Cappiello, MG ;
Sutterwala, FS ;
Trinchieri, G ;
Mosser, DM ;
Ma, XJ .
JOURNAL OF IMMUNOLOGY, 2001, 166 (07) :4498-4506
[6]   The molecular biology of chronic myeloid leukemia [J].
Deininger, MWN ;
Goldman, JM ;
Melo, JV .
BLOOD, 2000, 96 (10) :3343-3356
[7]   PIP, A NOVEL IRF FAMILY MEMBER, IS A LYMPHOID-SPECIFIC, PU.1-DEPENDENT TRANSCRIPTIONAL ACTIVATOR [J].
EISENBEIS, CF ;
SINGH, H ;
STORB, U .
GENES & DEVELOPMENT, 1995, 9 (11) :1377-1387
[8]   Disabled-2 inactivation is an early step in ovarian tumorigenicity [J].
Fazili, Z ;
Sun, WP ;
Mittelstaedt, S ;
Cohen, C ;
Xu, XX .
ONCOGENE, 1999, 18 (20) :3104-3113
[9]   Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis [J].
Fehr, T ;
Schoedon, G ;
Odermatt, B ;
Holtschke, T ;
Schneemann, M ;
Bachmann, MF ;
Mak, TW ;
Horak, I ;
Zinkernagel, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (05) :921-931
[10]   DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases [J].
Fulop, V ;
Colitti, CV ;
Genest, D ;
Berkowitz, RS ;
Yiu, GK ;
Ng, SW ;
Szepesi, J ;
Mok, SC .
ONCOGENE, 1998, 17 (04) :419-424